EGF and cancer: Previous work revealed PKM2 is translocated to the nucleus in human cancer cells in response to EGF, a process resulting from PKM2 successively binding to PIN1 (peptidylprolyl cis/trans isomerase, NIMA-interacting 1) and importin α5 [12].